[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patients-with-critically-ill-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patients-with-critically-ill-infections":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100588317","phase-4-a-multicenter-clinical-study-on-the-continuous-vs-intermittent-infusion-of-ceftazidime-avibactam-in-critically-ill-patients-with-severe-infections-100588317",false,"NCT06939829","A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","AVIATOR","Inclusion Criteria:\n\n* 18-85 years old, male or female.\n* Patients who are admitted to ICU wards.\n* Patients clinically diagnosed with carbapenem-resistant organism (CRO) infections, and has been commenced on targeted therapy with ceftazidime-avibactam.\n* One or more organ dysfunction criteria in the previous 24 hours i. MAP \\\u003C 60 mmHg for at least 1 hour; ii. Vasopressors required for \\> 4 hours; iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour.\n\niv. Serum creatinine concentration \\> 220 μmol\u002FL or \\>2.49 mg\u002FdL\n\nExclusion Criteria:\n\n* Patient has a known allergy to ceftazidime-avibactam.\n* Patient has received ceftazidime-avibactam for more than 48 hours during current infectious episode.\n* Patient is in severe condition or expected to survive for no more than 48 hours.\n* Patient who receives lung or heart transplant or stem cell transplant.\n* Patient is known or suspected to be pregnant.\n* Patient has previously been enrolled in the current study.\n* Other conditions which are regarded as inappropriate for enrollment.","ALL","18 Years","85 Years",{"count":21,"type":22},1200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The objective of this study is to determine whether continuous infusion of ceftazidime-avibactam (CAZ-AVI) could improve clinical outcomes in critically ill patients compared with intermittent infusion.",[28],"Patients With Critically Ill Infections",[30,31,32],"Ceftazidime-Avibactam","Continuous versus Intermittent Infusion","clinical study","NOT_YET_RECRUITING","2025-04-15",{"date":36,"type":37},"2025-04-23","ACTUAL",{"date":39,"type":22},"2025-05-01",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"Southeast University, China","OTHER"]